Tectonic Therapeutic, Inc.
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$74.2M
- Total assets
- $261.0M
- Market cap
- $547.2M
- Operating margin
- 104.6%
- Net margin
- 92.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- -$80.3M
- Operating expenses
- $84.0M
- Operating income
- -$84.0M
- Income tax
- $1.2M
- Net income
- -$74.2M
- EPS (basic)
- $-4.05
- EPS (diluted)
- $-4.05
Balance sheet
- Total assets
- $261.0M
- Current assets
- $257.4M
- Total liabilities
- $9.7M
- Current liabilities
- $9.7M
- Shareholders’ equity
- $251.3M
Cash flow
- Operating cash flow
- -$60.1M
- Investing cash flow
- -$138.0K
- Financing cash flow
- $173.4M
- Net cash flow
- $113.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $547.2M
- EPS (diluted)
- $-4.05
- Shares outstanding
- 19.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 21, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $74.2M.
- Revenue declined 48% from FY2024 to FY2025.
- Trading 22% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Tectonic Therapeutic, Inc..
Write a review
News about Tectonic Therapeutic, Inc.
News & sentiment via Polygon.io
